Article citationsMore>>

Lim, Y.Y., Hassenstab, J., Cruchaga, C., Goate, A., Fagan, A.M., Benzinger, T.L.S., Maruff, P., Snyder, P.J., Masters, C.L., Allegri, R., Chhatwal, J., Farlow, M.R., Graff-Radford, N.R., Laske, C., Levin, J., McDade, E., Ringman, J.M., Rossor, M., Salloway, S., Schofield, P.R., Holtzman, D.M., Morris, J.C. and Bateman, R.J. (2016) BDNF Val66Met Moderates Memory Impairment, Hippocampal Function and Tau in Preclinical Autosomal Dominant Alzheimer’s Disease. Brain, 139, 2766-2777.
https://doi.org/10.1093/brain/aww200

has been cited by the following article:

• TITLE: BDNF Gene Therapy: A Potential Solution for Neurodegenerative Diseases

  AUTHORS: Tanish Katkar

  KEYWORDS: Component, Formatting, Style, Styling, Insert

  JOURNAL NAME: Open Access Library Journal, Vol.12 No.2, February 19, 2025

  ABSTRACT: The research article explores the therapeutic potential of Brain-Derived Neurotrophic Factor (BDNF) gene therapy for Alzheimer’s Disease (AD). AD is characterized by neurofibrillary tangles and amyloid-beta plaques, which contribute to neuronal degradation and cognitive decline. BDNF plays a crucial role in neuronal survival, growth, synaptic plasticity, and cognitive functions like learning and memory. AD patients exhibit reduced BDNF levels, particularly in the cortex and hippocampus. BDNF gene therapy aims to elevate BDNF levels, counteracting synaptic dysfunction and neuronal degradation. While promising, the therapy faces challenges related to targeted delivery, precise regulation of BDNF expression, and ethical considerations. The article discusses the molecular mechanisms of BDNF in AD, its role in synaptic plasticity, and the interplay between reduced BDNF and amyloid deposition. It also explores innovative approaches such as BDNF mimetic compounds and combination therapies with disease-modifying agents like CF3CN. The article concludes by highlighting the need for further research to address the technical and biological challenges and to optimize BDNF gene therapy for improved clinical outcomes in AD and potentially other neurodegenerative diseases.